Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naveen S Basappa

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 4, 2020
Determining generalizability of the Canadian Kidney Cancer information system (CKCis) to the entire Canadian kidney cancer populationCamilla Tajzler, Simon Tanguay, Ranjeeta Mallick, et al.
Clinical Genitourinary Cancer|May 7, 2019
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205Sebastien J Hotte, Kim N Chi, Anthony M Joshua, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 8, 2018
Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trialsPierre I Karakiewicz, Emanuele Zaffuto, Anil Kapoor, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 15, 2023
Adjuvant therapy for renal cell carcinoma: 2023 Canadian Kidney Cancer Forum consensus statementAly-Khan A Lalani, Anil Kapoor, Naveen S Basappa, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|February 21, 2024
Addressing controversial areas in the management of advanced prostate cancer in Canada Areas of consensus and controversy from the third Canadian consensus forumFred Saad, Sebastien J Hotte, Krista Noonan, et al.
JAMA Network Open|April 15, 2026
Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell CarcinomaMartin Zarba, Eddy Saad, Karl Semaan, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 9, 2019
Controversial issues in the management of patients with advanced prostate cancer: Results from a Canadian consensus forumFred Saad, Christina Canil, Antonio Finelli, et al.
The Lancet. Oncology|March 1, 2023
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label studyToni K Choueiri, Masatoshi Eto, Robert Motzer, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 14, 2021
Results from a Canadian consensus forum of key controversial areas in the management of advanced prostate cancer: Recommendations for Canadian healthcare providersFred Saad, Sebastien J Hotte, Antonio Finelli, et al.
Nature Communications|February 27, 2026
Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancerDavid C Müller, Andrew J Murtha, Jack V W Bacon, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 4, 2020
Determining generalizability of the Canadian Kidney Cancer information system (CKCis) to the entire Canadian kidney cancer populationCamilla Tajzler, Simon Tanguay, Ranjeeta Mallick, et al.
Clinical Genitourinary Cancer|May 7, 2019
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205Sebastien J Hotte, Kim N Chi, Anthony M Joshua, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 8, 2018
Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trialsPierre I Karakiewicz, Emanuele Zaffuto, Anil Kapoor, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 15, 2023
Adjuvant therapy for renal cell carcinoma: 2023 Canadian Kidney Cancer Forum consensus statementAly-Khan A Lalani, Anil Kapoor, Naveen S Basappa, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|February 21, 2024
Addressing controversial areas in the management of advanced prostate cancer in Canada Areas of consensus and controversy from the third Canadian consensus forumFred Saad, Sebastien J Hotte, Krista Noonan, et al.
JAMA Network Open|April 15, 2026
Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell CarcinomaMartin Zarba, Eddy Saad, Karl Semaan, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 9, 2019
Controversial issues in the management of patients with advanced prostate cancer: Results from a Canadian consensus forumFred Saad, Christina Canil, Antonio Finelli, et al.
The Lancet. Oncology|March 1, 2023
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label studyToni K Choueiri, Masatoshi Eto, Robert Motzer, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 14, 2021
Results from a Canadian consensus forum of key controversial areas in the management of advanced prostate cancer: Recommendations for Canadian healthcare providersFred Saad, Sebastien J Hotte, Antonio Finelli, et al.
Nature Communications|February 27, 2026
Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancerDavid C Müller, Andrew J Murtha, Jack V W Bacon, et al.
Pageof 6